Equities Analysts Offer Predictions for DNLI FY2024 Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Wedbush reduced their FY2024 earnings estimates for shares of Denali Therapeutics in a research report issued to clients and investors on Thursday, November 7th. Wedbush analyst L. Chico now expects that the company will post earnings of ($2.72) per share for the year, down from their previous forecast of ($2.49). Wedbush has a "Outperform" rating and a $26.00 price objective on the stock. The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.62) per share. Wedbush also issued estimates for Denali Therapeutics' Q4 2024 earnings at ($0.82) EPS, Q1 2025 earnings at ($0.83) EPS, Q2 2025 earnings at ($0.83) EPS, Q3 2025 earnings at ($0.84) EPS, Q4 2025 earnings at ($0.84) EPS, FY2025 earnings at ($3.34) EPS, FY2026 earnings at ($3.08) EPS, FY2027 earnings at ($2.29) EPS and FY2028 earnings at ($0.86) EPS.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter last year, the business earned ($0.72) earnings per share.

Other analysts also recently issued research reports about the stock. Raymond James reiterated a "market perform" rating on shares of Denali Therapeutics in a report on Thursday, October 10th. Citigroup boosted their price objective on Denali Therapeutics from $26.00 to $32.00 and gave the company a "buy" rating in a report on Friday, August 2nd. Jefferies Financial Group raised their target price on Denali Therapeutics from $40.00 to $45.00 and gave the company a "buy" rating in a report on Friday, November 1st. HC Wainwright reaffirmed a "buy" rating and issued a $90.00 target price on shares of Denali Therapeutics in a research report on Thursday. Finally, Cantor Fitzgerald cut shares of Denali Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Monday, October 7th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $38.90.

Denali Therapeutics Stock Up 0.7 %

DNLI stock traded up $0.23 during mid-day trading on Monday, hitting $31.58. 797,116 shares of the company were exchanged, compared to its average volume of 1,069,696. The business has a fifty day simple moving average of $27.95 and a 200-day simple moving average of $23.73. The firm has a market capitalization of $4.54 billion, a P/E ratio of -11.44 and a beta of 1.40. Denali Therapeutics has a 12-month low of $14.56 and a 12-month high of $33.33.

Insider Buying and Selling at Denali Therapeutics

In related news, Director Steve E. Krognes sold 30,000 shares of the business's stock in a transaction on Monday, September 30th. The shares were sold at an average price of $29.03, for a total transaction of $870,900.00. Following the completion of the transaction, the director now owns 29,096 shares in the company, valued at approximately $844,656.88. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, CEO Ryan J. Watts sold 40,000 shares of the business's stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $27.69, for a total transaction of $1,107,600.00. Following the completion of the sale, the chief executive officer now owns 235,807 shares in the company, valued at approximately $6,529,495.83. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Steve E. Krognes sold 30,000 shares of the stock in a transaction on Monday, September 30th. The shares were sold at an average price of $29.03, for a total transaction of $870,900.00. Following the completion of the transaction, the director now directly owns 29,096 shares in the company, valued at $844,656.88. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 7.90% of the company's stock.

Institutional Trading of Denali Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. EP Wealth Advisors LLC purchased a new stake in Denali Therapeutics in the 1st quarter valued at $831,000. Edgestream Partners L.P. purchased a new stake in shares of Denali Therapeutics in the first quarter valued at about $2,301,000. Swiss National Bank boosted its stake in shares of Denali Therapeutics by 0.7% during the first quarter. Swiss National Bank now owns 218,200 shares of the company's stock worth $4,477,000 after buying an additional 1,500 shares during the period. Bayesian Capital Management LP purchased a new position in shares of Denali Therapeutics during the first quarter worth about $447,000. Finally, Capital Research Global Investors increased its position in Denali Therapeutics by 107.9% in the 1st quarter. Capital Research Global Investors now owns 6,049,957 shares of the company's stock valued at $124,145,000 after acquiring an additional 3,140,429 shares during the period. Institutional investors and hedge funds own 92.92% of the company's stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.